Related Experiment Videos
Eradication therapies for Helicobacter pylori
T J Borody1, N P Shortis, E Reyes
1Centre for Digestive Diseases, Five Dock, NSW, Australia.
Journal of Gastroenterology
|December 5, 1998
Summary
Proton pump inhibitor (PPI)-based therapies, particularly quadruple therapy, offer over 90% Helicobacter pylori eradication success. Choosing effective regimens is crucial to prevent antibiotic resistance and difficult-to-treat infections.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Pharmacology
Background:
- Helicobacter pylori eradication therapies have evolved significantly over decades.
- Early treatments included monotherapy, dual, and triple therapies.
- The introduction of proton pump inhibitors (PPIs) and clarithromycin revolutionized treatment development.
Purpose of the Study:
- To review the evolution and current landscape of H. pylori eradication therapies.
- To identify highly effective regimens achieving over 90% eradication rates.
- To highlight the risks associated with suboptimal treatment strategies.
Main Methods:
- Review of therapeutic trials and clinical data on H. pylori eradication.
- Comparison of different combination therapies, including PPI-based regimens.
- Analysis of factors contributing to treatment failure and antibiotic resistance.
Main Results:
- Two PPI-based therapies consistently achieve over 90% H. pylori eradication.
- PPI/amoxicillin/clarithromycin is simple but potentially costly.
- 7-day quadruple therapy (PPI, bismuth, tetracycline, metronidazole) is effective, overcomes resistance, and shows high eradication rates.
Conclusions:
- High first-time eradication success is essential for managing H. pylori infections.
- Failure to use effective regimens increases the pool of patients with resistant strains.
- Quadruple therapy is emerging as a robust, all-around treatment option for H. pylori.